BDTX
Black Diamond Therapeutics Inc

2,668
Mkt Cap
$228.47M
Volume
1.71M
52W High
$4.94
52W Low
$1.20
PE Ratio
11.05
BDTX Fundamentals
Price
$4.01
Prev Close
$4.49
Open
$4.15
50D MA
$3.77
Beta
1.76
Avg. Volume
860,819.78
EPS (Annual)
-$1.27
P/B
1.81
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
What is HC Wainwright's Forecast for BDTX FY2025 Earnings?
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX - Free Report) - Research analysts at HC Wainwright boosted their FY2025 EPS estimates for Black Diamond Therapeutics in a note issued to investors on...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Zacks·4d ago
News Placeholder
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?
Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·4d ago
News Placeholder
Black Diamond Therapeutics (NASDAQ:BDTX) Releases Earnings Results
Black Diamond Therapeutics (NASDAQ:BDTX - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.22...
MarketBeat·9d ago
News Placeholder
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
Zacks·16d ago
News Placeholder
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
Zacks·25d ago
News Placeholder
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
Zacks·1mo ago
News Placeholder
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
Zacks·1mo ago
News Placeholder
Is Medpace (MEDP) Outperforming Other Medical Stocks This Year?
Here is how Medpace (MEDP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Zacks·1mo ago
News Placeholder
Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue?
Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·1mo ago

Latest BDTX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.